Effect of Add-on L-Arginine Therapy on Heart Failure Patients

German University in Cairo

Status and phase: Not yet enrolling; Phase 2

Conditions: Heart Failure

Treatments: Drug: L-Arginine Powder; Drug: Placebo

Study type: Interventional

Funder types: Other

Identifiers

NCT07394270

CPH-2025-07-MHS

Details and patient eligibility

About

Heart failure is considered one of the greatest challenges globally. There are various treatment strategies for heart failure. L-Arginine is an amino acid that was found to have beneficial effect on vasculature. This study aims to study the benefits and side effects of using L-arginine on the patients with ejection fraction <40%

Enrollment: 200 estimated patients

Sex: All

Ages: 19+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with EF <40%
• eGFR >30 mL/min/1.73 m2
• Stable patients
• Capable and willing to provide written consent

Exclusion criteria

• Patients with implantable cardioverter-defibrillator
• Pregnant or lactating fmeales
• Patients with a history of sensitivity to L-Arginine or any of the excipients
• Acute heart failure patients
• Patients use L-arginine supplementation.
• Patients with active herpes disease

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

200 participants in 2 patient groups, including a placebo group

L-Arginine Arm

Active Comparator group

Description:

Patients in this arm will be administered 6 gm L-arginine per day

Treatment:

Drug: L-Arginine Powder

Placebo Arm

Placebo Comparator group

Description:

Patients in this arm will take 6 gm placebo per day

Treatment:

Drug: Placebo